Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Abbvie inc. symbols : FNCTF save search
Myopia and presbyopia treatment market size to grow by USD 7.94 billion from 2022 to 2027, Major Vendors include AbbVie Inc., Alcon Inc. and Arctic Vision, Technavio
Published: 2024-02-28 (Crawled : 17:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -1.4%
H: 0.0%
C: -0.01%
BHC | $8.53 0.95% 0.0% 4M
|
Health Technology
|
| O: 0.11%
H: 2.23%
C: 0.11%
ALC | $80.76 0.19% 0.0% 940K
|
Health Technology
|
| O: 4.09%
H: 1.72%
C: 1.41%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.6%
H: 0.02%
C: -1.03%
abbvie presbyopia treatment market
HIV Drugs Market to Reach $51.1 Billion, Globally, by 2032 at 4.5% CAGR: Allied Market Research
Published: 2023-11-17 (Crawled : 16:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.69%
H: 0.06%
C: -0.68%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.5%
H: 0.82%
C: 0.75%
reach research hiv market
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
imbruvica meeting
AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting
Published: 2022-11-22 (Crawled : 21:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.1%
H: 0.62%
C: -0.35%
blood meeting growing cancer
Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)
Published: 2022-08-24 (Crawled : 00:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.62%
H: 0.57%
C: 0.4%
imbruvica disease children
AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
Published: 2022-05-12 (Crawled : 16:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 0.2%
H: 0.0%
C: -1.1%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: -1.14%
H: 6.45%
C: 4.23%
asco
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
imbruvica disease
AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
Published: 2021-11-04 (Crawled : 13:00) - prnewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.89%
H: 0.13%
C: -0.43%
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 0.56%
H: 2.78%
C: -0.81%
blood cancer research
Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness
Published: 2021-10-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.05%
H: 0.23%
C: -0.72%
aesthetic cancer breast cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.